New Data Reveal Medtronic CRT Devices Improve Therapy ... | 合法醫療器材資訊網

2017年7月6日—Byimprovingdevicelongevity,therearesubstantiallyfewerdevicereplacementsand,inturn,significantcostsavingsandfewerprocedure- ...

July 6, 2017 — New data showed use of Medtronic’s cardiac resynchronization therapy (CRT) devices[1] with its proprietary AdaptivCRT and EffectiveCRT algorithms results in lower healthcare system costs, and improves therapy delivery in heart failure patients who also have atrial fibrillation (AF). The results of three analyses were presented at the European Heart Rhythm Association (EHRA) EUROPACE-CARDIOSTIM 2017, June 18-21 in Vienna, Austria.

Findings from a European health-economic analysis demonstrated that treating patients with AdaptivCRT results in lower healthcare costs and extends life expectancy by an average of four months. The findings, which span three countries healthcare systems, showed that lifetime costs for patients treated with AdaptivCRT were lower than for patients treated with traditional pacing algorithms: